Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

One-year Phase III Study Confirms Ilaris(R) Offers Long-term Remission In Patients With CAPS, A Severe Lifelong Auto-inflammatory Disease
New results from a one-year Phase III study have confirmed that the investigational biological therapy Ilaris® (canakinumab, formerly ACZ885)[1] produced rapid and sustained remission of symptoms in the majority of children and adults with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS)1,2,3.
pharmacy online
The Mystery Of Why HIV Patients Are More Susceptible To TB Infection Solved By Harvard Scientists
A team of Harvard scientists has taken an important first step toward the development of new treatments to help people with HIV battle Mycobacterium tuberculosis (TB) infection. In their report, appearing in the July 2009 print issue of the Journal of Leukocyte Biology they describe how HIV interferes with the cellular and molecular mechanisms used by the lungs to fight TB infection. This information is crucial for researchers developing treatments to help people with HIV prevent or recover from TB infection.
News of the day
MacroGenics And Lilly Achieve Targeted Patient Enrollment In PROTEGE, A Global Phase 2/3 Clinical Trial Of Teplizumab In Type 1 Diabetes
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.
Mental Health

Withdrawal Of Co-proxamol Linked To Reduction In Suicides And Accidental Poisonings, UK

Withdrawal of the painkiller co-proxamol from the UK market has led to a major reduction in suicides and accidental poisonings involving the drug, without an increase in deaths from other painkillers, finds research published on bmj.com today. Co-proxamol was the most commonly prescribed drug used in suicides and was responsible for 766 deaths between 1997 and 1999 in England and Wales. Concerns about large numbers of fatal poisonings led the Committee on Safety in Medicines to announce in 2005 the phasing out of co-proxamol from use in the UK by the end of 2007. Whether this initiative has been effective and reduced poisoning deaths has not been assessed. So Keith Hawton from the University of Oxford and colleagues used national records to compare the impact of the announcement of co-proxamol withdrawal on prescribing practices and deaths from co-proxamol with other painkillers mostly likely to be used instead of co-proxamol (cocodamol, codeine, codydramol, dihydrocodeine, non-steroid anti-inflammatory drugs) in England and Wales between 1998 and 2007. Findings showed a steep fall (59%), in the prescribing of co-proxamol following the announcement in 2005, accompanied by significant increases in the prescribing of other painkillers including cocodamol (up by more than 20%), paracetamol (up by more than 13%), and codeine (up by more than 8%). These changes in prescribing practices were accompanied by a 62% reduction in, or 295 fewer suicides, and 349 fewer deaths when accidental poisonings were included, without an increase in deaths involving other painkillers and prescribed drugs. This, say the authors, shows that concerns about the possible substitution of suicide method involving other painkillers were unfounded. These findings suggest that the UK initiative has been an effective measure and highlights how regulatory authorities "can have an important public health function, as has been found for measures restricting pack sizes of analgesics sold over the counter," they conclude. British Medical Journal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009